MA38646A1 - Formulation a liberation modifiee pour traiter, par ex. La maladie de parkinson et la dyskinesie induite par l-dopa. - Google Patents

Formulation a liberation modifiee pour traiter, par ex. La maladie de parkinson et la dyskinesie induite par l-dopa.

Info

Publication number
MA38646A1
MA38646A1 MA38646A MA38646A MA38646A1 MA 38646 A1 MA38646 A1 MA 38646A1 MA 38646 A MA38646 A MA 38646A MA 38646 A MA38646 A MA 38646A MA 38646 A1 MA38646 A1 MA 38646A1
Authority
MA
Morocco
Prior art keywords
dopa
modified release
parkinson
treating
disease
Prior art date
Application number
MA38646A
Other languages
English (en)
Other versions
MA38646B1 (fr
Inventor
Arnaud Grandeury
Mike Ufer
Bruno Galli
Hubert Thoma
Dirk Spickermann
Karsten Putzbach
Klaus-Peter Moll
Jean-Marie Glantzmann
Martin Mueller-Zsigmondy
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51211272&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA38646(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MA38646A1 publication Critical patent/MA38646A1/fr
Publication of MA38646B1 publication Critical patent/MA38646B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J3/00—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
    • A61J3/02—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms into the form of powders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J3/00—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
    • A61J3/10—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms into the form of compressed tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5089—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Inorganic Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Cette invention concerne des produits médicamenteux sous la forme de formulations à libération modifiée comprenant la substance médicamenteuse, ester méthylique d'acide (-)-(3ar,4s,7ar)-4-hydroxy-4m-tolyléthynyl-octahydro-indole-1-carboxylique (afq056), ainsi que des procédés pour les fabriquer. Les produits médicamenteux selon l'invention sont utiles pour traiter les patients atteints de la maladie de parkinson et présentant une dyskinésie induite par la l-dopa.
MA38646A 2013-06-12 2014-06-11 Formulation a liberation modifiee pour traiter, par ex. La maladie de parkinson et la dyskinesie induite par l-dopa. MA38646B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361834104P 2013-06-12 2013-06-12
PCT/IB2014/062136 WO2014199316A1 (fr) 2013-06-12 2014-06-11 Formulation à libération modifiée

Publications (2)

Publication Number Publication Date
MA38646A1 true MA38646A1 (fr) 2017-09-29
MA38646B1 MA38646B1 (fr) 2018-04-30

Family

ID=51211272

Family Applications (1)

Application Number Title Priority Date Filing Date
MA38646A MA38646B1 (fr) 2013-06-12 2014-06-11 Formulation a liberation modifiee pour traiter, par ex. La maladie de parkinson et la dyskinesie induite par l-dopa.

Country Status (22)

Country Link
US (3) US20160128979A1 (fr)
EP (1) EP3007682B1 (fr)
JP (1) JP6444996B2 (fr)
KR (1) KR102290249B1 (fr)
CN (2) CN111467313A (fr)
AU (1) AU2014279743B2 (fr)
BR (1) BR112015030431B1 (fr)
CA (1) CA2911486C (fr)
CL (1) CL2015003596A1 (fr)
EA (1) EA031395B1 (fr)
ES (1) ES2644698T3 (fr)
HK (1) HK1216839A1 (fr)
MA (1) MA38646B1 (fr)
MX (1) MX369742B (fr)
PE (1) PE20160183A1 (fr)
PH (1) PH12015502556A1 (fr)
PL (1) PL3007682T3 (fr)
PT (1) PT3007682T (fr)
SG (1) SG11201509178TA (fr)
TN (1) TN2015000498A1 (fr)
WO (1) WO2014199316A1 (fr)
ZA (1) ZA201508228B (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2930848T3 (es) 2015-09-23 2022-12-22 Xwpharma Ltd Profármacos de ácido gamma-hidroxibutírico, composiciones y usos de los mismos
AU2018310881C1 (en) * 2017-07-31 2021-12-16 Novartis Ag Use of mavoglurant in the reduction of cocaine use or in preventing relapse into cocaine use
KR20200035262A (ko) * 2017-07-31 2020-04-02 노파르티스 아게 알코올 사용 감소 또는 알코올 사용 재발 예방에 있어서 마보글루란트의 용도
AU2020215849B2 (en) 2019-01-29 2023-07-27 Novartis Ag The use of an mGluR5 antagonist for treating opioid analgesic tolerance
EP4181918A2 (fr) 2020-07-17 2023-05-24 Novartis AG Utilisation d'antagonistes de mglur5
JP2023552833A (ja) 2020-12-11 2023-12-19 ノバルティス アーゲー アンフェタミン中毒の治療のためのｍＧｌｕＲ５拮抗薬の使用
WO2022130136A1 (fr) 2020-12-14 2022-06-23 Novartis Ag Utilisation d'antagonistes de mglur5 pour traiter un trouble lié aux jeux d'argent

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030118641A1 (en) 2000-07-27 2003-06-26 Roxane Laboratories, Inc. Abuse-resistant sustained-release opioid formulation
GB0128996D0 (en) 2001-12-04 2002-01-23 Novartis Ag Organic compounds
WO2005018921A1 (fr) * 2003-08-25 2005-03-03 Alpex Pharma Sa Tablet punches and method for tableting
GB0514296D0 (en) * 2005-07-12 2005-08-17 Novartis Ag Organic compounds
CN101360725B (zh) * 2005-11-18 2011-09-21 阿斯利康公司 固体制剂
US20070141148A1 (en) * 2005-11-30 2007-06-21 Merz Pharma Gmbh & Co. Kgaa Neramexane MR matrix tablet
US20080085305A1 (en) 2006-10-10 2008-04-10 Penwest Pharmaceuticals Co. Robust sustained release formulations of oxymorphone
CA2930487A1 (fr) 2007-01-16 2008-07-24 Egalet Ltd. Utilisation (i) d'un polyglycol et (ii) d'une substance medicamenteuse active dans la preparation d'une composition pharmaceutique destinee (i) a reduire le risque de liberation massive induite par l'alcool et/ou (ii) a reduire le risque de toxicomanie medicamenteuse
CA2751761A1 (fr) * 2008-10-22 2010-04-29 House Ear Institute Traitement therapeutique et/ou prophylactique de pathologies de l'oreille interne par la modulation du recepteur metabotropique du glutamate
US20120039999A1 (en) * 2010-08-11 2012-02-16 Ashish Chatterji Pharmaceutical compositions of metabotropic glutamate 5 receptor (mglu5) antagonists
US20120040008A1 (en) * 2010-08-11 2012-02-16 Ashish Chatterji Pharmaceutical compositions of metabotropic glutamate 5 receptor (mglu5) antagonists
WO2012085167A1 (fr) * 2010-12-22 2012-06-28 Merz Pharma Gmbh & Co. Kgaa Modulateurs des récepteurs glutamatergiques métabotropes
WO2012139876A1 (fr) 2011-04-14 2012-10-18 Merz Pharma Gmbh & Co. Kgaa Formulations entériques de modulateurs de récepteur de glutamate métabotropique

Also Published As

Publication number Publication date
KR20160018702A (ko) 2016-02-17
MX369742B (es) 2019-11-20
EP3007682A1 (fr) 2016-04-20
HK1216839A1 (zh) 2016-12-09
TN2015000498A1 (en) 2017-04-06
JP6444996B2 (ja) 2018-12-26
JP2016520663A (ja) 2016-07-14
PT3007682T (pt) 2017-11-02
MA38646B1 (fr) 2018-04-30
AU2014279743A1 (en) 2015-11-26
CA2911486C (fr) 2021-09-21
AU2014279743B2 (en) 2017-05-25
CN105263479A (zh) 2016-01-20
PH12015502556A1 (en) 2016-02-22
KR102290249B1 (ko) 2021-08-17
US20230355582A1 (en) 2023-11-09
CA2911486A1 (fr) 2014-12-18
EA201690005A1 (ru) 2016-04-29
SG11201509178TA (en) 2015-12-30
PL3007682T3 (pl) 2017-12-29
US20210069150A1 (en) 2021-03-11
BR112015030431A2 (pt) 2017-07-25
ES2644698T3 (es) 2017-11-30
CN111467313A (zh) 2020-07-31
BR112015030431B1 (pt) 2023-02-28
WO2014199316A1 (fr) 2014-12-18
ZA201508228B (en) 2016-11-30
EA031395B1 (ru) 2018-12-28
US20160128979A1 (en) 2016-05-12
PE20160183A1 (es) 2016-04-28
CL2015003596A1 (es) 2016-09-02
MX2015017202A (es) 2016-11-11
EP3007682B1 (fr) 2017-07-26

Similar Documents

Publication Publication Date Title
MA38646B1 (fr) Formulation a liberation modifiee pour traiter, par ex. La maladie de parkinson et la dyskinesie induite par l-dopa.
CY1123945T1 (el) Στοματικα σκευασματα αμεσης απελευθερωσης για υποκατεστημενες κιναζολινονες
MX2018012901A (es) Formulaciones de inhibidor de demetilasa 1 especifica para lisina (lsd1).
MX2014014902A (es) Composiciones que comprenden apomorfina y acidos organicos y usos de las mismas.
BR112019024747A2 (pt) formulações de dose fixa
MA37206B1 (fr) Nouveaux derives de pyrrole, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
MA33295B1 (fr) Nouvelle formulation de diclofénac
TW200637614A (en) Bendamustine pharmaceutical compositions
MA37610B1 (fr) Formulations de testostérone proliposomales
UA104869C2 (uk) Фармацевтичні композиції, що містять ліганди рецептора дофаміну
MX357780B (es) Derivados policíclicos, proceso para su preparación y su uso farmacéutico.
EP3760638A3 (fr) Compositions et procédés utilisant des échafaudages de lysophosphatidylcholine
EA201490653A1 (ru) Производные эстра-1,3,5(10),16-тетраен-3-карбоксамида, способ их получения, содержащие их фармацевтические препараты, а также их применение для получения лекарственных средств
UA94036C2 (ru) Фармацевтическая композиция бендамустина, предназначенная для лиофилизации
EA201500112A1 (ru) 3-замещенные производные эстра-1,3,5(10),16-тетраена, способы их получения, фармацевтические средства, которые их содержат, и их использование для получения лекарственных средств
MX2015001917A (es) Composiciones farmaceuticas de memantina.
MX2018004109A (es) Activadores de flujo autofágico y fosfolipasa d y depuración de acumulaciones de proteína que incluyen tau y tratamiento de proteinopatías.
PH12015500823A1 (en) Modified release formulations for oprozomib
BR112015029897A2 (pt) composição sólida para administração oral contendo ácido ibandrônico ou um seu sal farmaceuticamente aceitável e vitamina d e processo para obtenção da referida composição
BR112014027676A2 (pt) formulação de cápsula solubilizada de [(1s)-1-{[(2s,4r)-4-(7-cloro-4metóxi-isoquinolin-1-ilóxi)-2-({(1r,2s)-1-[(ciclopropilsulfonil)carbamoil]-2-etenilciclopropil}carbamoil)pirrolidin-1-il]carbonil}-2,2-dimetilpropil]carbamato de 1,1-dimetiletila
BRPI0917245A8 (pt) Compostos derivados de isoquinolinona e sua composição farmacêutica
WO2013192610A3 (fr) Promédicaments du riluzole et leur procédé d'utilisation pour le traitement d'une sclérose latérale amyotrophique
EA201790315A1 (ru) Модуляторы x-рецепторов печени
MA39448A1 (fr) (r)-pirlindole et ses sels pharmaceutiquement acceptables destinés à un usage médical
JOP20190178A1 (ar) تركيبة صيدلانية تتضمن مشتق أوكسازين واستخدامها في علاج أو الوقاية من مرض الزهايمر